SCHEMBL3225634

SCHEMBL3225634

CCOC(=O)CN(C(=O)Oc1ccc(OC)cc1)c1cc(Cl)c(Oc2ccc(OC)c(CC)c2)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
PPARG P37231 1/20 0.38
THRB P10828 2/20 0.36
RORC P51449 2/20 0.36
LIPE Q05469 1/20 0.35
HSD17B10 Q99714 1/20 0.35
USP2 O75604 2/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
TSPO P30536 1/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 1/20 0.34
ATM Q13315 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3213016 0.92 THRB (0.38) ALDH1A1PPARGTHRBRORCHSD17B10
SCHEMBL3221169 0.90 THRB (0.39) ALDH1A1PPARGTHRBRORCLIPE
SCHEMBL3217882 0.88 ALDH1A1 (0.38) ALDH1A1PPARGTHRBRORCLIPE
SCHEMBL3217778 0.88 RORC (0.52) ALDH1A1PPARGTHRBRORC
SCHEMBL3227152 0.87 POLB (0.46) ALDH1A1PPARGLMNATSHRSMN1; SMN2
SCHEMBL3231826 0.87 ALDH1A1 (0.37) ALDH1A1PPARGTHRBRORCLIPE
SCHEMBL3219867 0.87 THRB (0.40) ALDH1A1PPARGTHRBRORCHSD17B10
SCHEMBL3226111 0.87 THRB (0.43) ALDH1A1PPARGTHRBRORC
SCHEMBL3225821 0.87 THRB (0.40) ALDH1A1PPARGTHRBRORCLIPE
SCHEMBL3221572 0.86 POLB (0.44) ALDH1A1PPARGLMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420851-B2 Selective TR-β 1 agonist CADILA HEALTHCARE LIMITED (IN) 2013-04-16 US claimed
EP-2079678-B1 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LTD (IN) 2012-12-19 EP claimed
US-20100048550-A1 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LIMITED (IN) 2010-02-25 US claimed
EP-2079678-A2 SELECTIVE TR-BETA 1 AGONIST Cadila Healthcare Limited (IN) 2009-07-22 EP claimed
WO-2008062469-A2 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LIMITED (IN) 2008-05-29 WO claimed
US-8420851-B2 Selective TR-β 1 agonist CADILA HEALTHCARE LIMITED (IN) 2013-04-16 US disclosed
EP-2079678-B1 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LTD (IN) 2012-12-19 EP disclosed
US-20100048550-A1 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LIMITED (IN) 2010-02-25 US disclosed
EP-2079678-A2 SELECTIVE TR-BETA 1 AGONIST Cadila Healthcare Limited (IN) 2009-07-22 EP disclosed
WO-2008062469-A2 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LIMITED (IN) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048550-A1 SELECTIVE TR-BETA 1 AGONIST THRB, THRA, TSHR ALDH1A1 1801/4885PPARG 104/4885THRB 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.